REFERENCES
Cannabis Aromatherapy
Appendino G, Gibbons S, Giana A et al. (2008). Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. The Journal of Natural Products. 71, p1427-1430.
Banerjee SP, Snyder SH and Mechoulam R. (1975). Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. Journal of Pharmacology and Experimental Therapeutics. 194, p74-81.
Beal, JE., Olson, R., Laubenstein, L., Morales, JO., Bellman, P., Yangco, B., Lefkowitz, L, Plasse, TF. and Shephard, KV. (1995, February). Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Journal of Pain and System Management, 10(2), 89-97.
Cawthorne MA, Wargent E, Zaibi M, Stott C and Wright S. (2007). The
CB1 antagonist, delta-9-tetrahydrocannabivarin (THCV) has antiobesity activity in dietary-induced obese (DIO) mice. Proceedings of the 17th Annual Symposium on the Cannabinoids. June 26-30, 2007, Saint-Sauveur, Québec, Canada. Unpublished conference paper.
Costa B, Trovato AE, Comelli F, Giagnoni G and Colleoni M. (2007). The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. The European Journal of Pharmacology. 556, p75-83.
De Petrocellis L and Di Marzo V. (2010). Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels. Journal of Neuroimmune Pharmacology. 5, p103-121.
De Petrocellis L, Ligresti A, Moriello AS et al. (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology. 163 (7), p1479-1494.
Hampson AJ, Grimaldi M, Axelrod J and Wink D. (1998). Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences. 95, p8268–8273.
Jones NA, Hill AJ, Smith I et al. (2010). Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. Journal of Pharmacology and Experimental Therapeutics. 332, p569–577.
Ligresti, A., Moriello, A.S., Starowicz, K., Matias, I., Pisanti, S., De Petrocellis, L., Laezza, C., Portella, G., Bifulco, M., and Di Marzo, V. (2006, September). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast
carcinoma. Journal of Pharacologogy and Experimental Therapeutics, 318(3), 1375-87.
Regelson W, Butler JR, Schuiz J et al. (1976). Delta-9-THC as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. The Pharmacology of Marihuana. New York: Raven Press. p763-775.
Riedel G, Fadda P, McKillop-Smith S et al. (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. British Journal of Pharmacology. 156, p1154-1166.
Russo E. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163, p1344-1364.
Russo E. (2006). The Solution to the Medicinal Cannabis Problem. Ethical Issues in Chronic Pain Management. Florida: Taylor & Francis. p165–194.
Russo EB, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66: p234–46. PubMed
Russo E, Burnett A, Hall B, and Parker KK. (2005). Agonistic properties of cannabidiol at 5-HT-1a receptors. Neurochemical Research. 30, p1037-1043.
Turner CE, Elsohly MA and Boeren EG. (1980). Constituents of Cannabis sativa L. XVII. A review of the natural constituents. The Journal of Natural Products. 43, p169–234.
Wilsey B et al. (2013). Low dose vaporized cannabis significantly improves neuropathic pain. The Journal of Pain. 14 (2), p136-148.
76 77